Degron Therapeutics added $40 million to its Series A, bringing total funding to $95 million, as its molecular glue degrader platform advanced into the clinic with DEG6498 — the first HuR-targeting molecular glue to reach clinical testing in advanced solid tumours in the U.S. and China. The company says the raise was driven by platform and pipeline milestones, including more than 10,000 molecular glue degraders generated across 150+ non-IMiD cores and a first patient dosed in November.

Why It Matters To Oncology

• DEG6498 targets HuR, an RNA-binding protein implicated in stabilising pro-cancer survival transcripts and overexpressed across multiple tumour types.

• HuR has been considered difficult to drug because it lacks a catalytic pocket for conventional small molecules and is not accessible to antibody approaches.

• Degron said preclinical work suggests BRAF-mutant tumours depend on HuR and that cancer cells resistant to current standard-of-care therapies remained sensitive to the HuR degrader, informing early patient-selection strategy.

The Financials

• The $40 million extension brings Degron’s total Series A financing to $95 million.

• The round was led by Lapam Capital, with participation from GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures and GAGE Capital.

• Separately, Takeda signed a 2024 discovery deal with Degron worth up to $1.2 billion spanning oncology, neuroscience and inflammation.

What They're Saying

• CEO Lily Zou said the financing was triggered by milestones across the biotech’s molecular glue degrader technology and pipeline.

• Zou argued Degron’s moat is its proprietary dataset: a structurally differentiated glue library plus proximity, degradation, structural and activity data that are difficult to reproduce.

• She also said the company is building AI tools on top of that dataset to support future molecular glue degrader discovery.

What's Next

• DEG6498 is now in clinical testing in advanced solid tumours, with initial development focused on translating preclinical sensitivity signals into biomarker-driven enrolment.

• Beyond oncology, Degron has added four discovery programmes since its 2022 Series A: two in autoimmune disease, one in metabolic disease and one in infectious disease.

• For clinicians in oncology drug discovery, the key watchpoint is whether HuR degradation can convert an undruggable cancer biology target into a clinically actionable strategy.